Oslo, 5 January 2025: Reference is made to the stock exchange announcement made
by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the
launch of Photocure's program to repurchase up to 300,000 of its own shares for
a total maximum amount of NOK 30 million during the period from 19 December
2024, until no later than 31 March 2025, pursuant to an agreement with DNB
Markets.

For the period from and including 19 December 2024, through 3 January 2024, the
Company purchased a total of 150,802 shares at an average price of NOK 62.43 per
share, all purchased as ordinary market purchases on Euronext Oslo Børs. Please
find below the transaction overview:

   Date     Aggregated daily   Weighted average       Total daily
            volume (#shares)  share price per day  transaction value
                                     (NOK)               (NOK)
19.12.2024       23,776              61.43             1,460,610
20.12.2024       21,764              62.95             1,370,150
23.12.2024       21,170              64.17             1,358,511
27.12.2024       16,547              64.29             1,063,742
30.12.2024       21,564              63.50             1,369,286
02.02.2025       22,401              61.77             1,383,629
03.01.2025       23,580              59.73             1,408,325

Total for       #shares        Weighted average    Total transaction
the period                     share price (NOK       value (NOK)
                150,802              62.43             9,414,253

No previously disclosed buybacks under the program.

Accumulated under  #shares  Weighted average  Total transaction value (NOK)
   the buyback              share price (NOK
     program
                   150,802       62.43                  9,414,253

The issuer's holding of own shares:
Following the completion of the above transactions, Photocure owns a total of
165,924 of own shares (including 15,122 shares owned prior to the launch of the
buyback program), corresponding to 0.61% of Photocure's share capital.

Appendix:
An overview of all transactions made under the buyback program that have been
carried out during the above-mentioned time period is attached to this report
and available at www.newsweb.no.

For further information, please contact:

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com and www.cysview.com. All trademarks mentioned in this release
are protected by law and are registered trademarks of Photocure ASA.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is made public by Photocure ASA pursuant to the EU Market Abuse
Regulation and subject to the disclosure requirements pursuant to Section 5-12
of the Norwegian Securities Trading Act.